Decrease in CA19-9 May Signal Survival Benefit in Patients With Pancreatic Cancer

Share this content:
Decrease in CA19-9 at week 8 identified more patients with survival benefit than radiologic response in patients with metastatic pancreatic cancer.
Decrease in CA19-9 at week 8 identified more patients with survival benefit than radiologic response in patients with metastatic pancreatic cancer.

Decrease in CA19-9 at week 8 identified more patients with survival benefit than radiologic response in patients with metastatic pancreatic cancer, according to a study published in the Annals of Oncology.1

The link between CA19-9 decreases and prolonged overall survival were investigated in an exploratory analysis of the phase 3 MPACT study, where patients were randomly assigned to receive nab-paclitaxel plus gemcitabine vs gemcitabine alone.

A total of 252 patients who received nab-paclitaxel and gemcitabine and 202 patients who received gemcitabine and had baseline and week 8 CA19-9 measurements were included in the study.

Results showed that patients with any CA19-9 decline (80%) vs those without (20%) demonstrated improved overall survival (median 11.1 months vs 8.0, respectively).

Patients in the combination arm with any decrease in CA19-9 (n = 206) at week 8 had a confirmed overall response rate of 40% vs 13% in those without a decrease and a median overall survival of 13.2 vs 8.3 months, respectively (P = .001). Patients in the gemcitabine alone arm with a decrease (n = 159) had a confirmed overall response rate of 15% vs 5% in those without a decrease at week 8.

RELATED: Overall Survival, Metabolic Response Higher in Pancreatic Cancer Treated With Nab-paclitaxel Plus Gemcitabine

Patients in the combination arm had an unconfirmed radiologic response of 16% vs 6% in the monotherapy arm at week 8 (median overall survival 13.7 months vs 14.7 months, respectively). Those with stable disease and any decrease in CA19-9 had a median overall survival of 13.2 months vs 9.4 months, respectively.

Reference

  1. Chiorean EG, Von Hoff DD, Reni M, et al. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine vs gemcitabine alone in patients with metastatic pancreatic cancer [published online ahead of print January 22, 2016]. Ann Oncol. doi: 10.1093/annonc/mdw006.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters